Allergen immunotherapy in treating allergic eosinophilic asthma

Czech version

Authors: Irena Krčmová; Jakub Novosad
Authors‘ workplace: Ústav klinické imunologie a alergologie, Lékařská fakulta Univerzity Karlovy, a Fakultní nemocnice Hradec Králové
Published in: Vnitř Lék 2022; 68(8): 517-524
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2022.110

Overview

Currently, the approach to a patient with asthma is in accordance with personalized medicine wherein the decision on the treatment pathway is based on the type of asthmatic inflammation and other comorbidities that accompany asthma. For an allergic asthma patient, allergen immunotherapy (AIT), which has a disease-modifying effect and the potential to prevent further progression of allergic symptoms, is one of the treatment modalities. It is an effective treatment that, unlike pharmacotherapy, modifies the course of allergic respiratory diseases and induces allergen specific immune tolerance that persists for up to several years after treatment cessation. Therapeutic allergens of high quality, efficacy, and safety according to European regulatory authorities are an integral part of the treatment of respiratory allergies. It is a safe treatment option which still remains the only causal immuno¬modulatory therapy for allergic eosinophilic asthma.

Keywords:

allergen immunotherapy – disease-modifying effect – allergic eosinophilic asthma

Sources

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2022 Update) https://ginasthma.org/gina‑reports.

2. Terl M, Sedlak V, Cap P et al. Asthma management: A new phenotype‑based approach using presence of eosinophilia and allergy. Allergy. 2017;72: 1279-1287. https://doi.org/10.1111/all.13165

3. Terl M, Pohunek P, Kuhn M, Bystron J. Four seasons of Czech asthma study: asthma characteristics and management reality in the Czech Republic. J Asthma. 2020;57(8):898-910.

4. Novosad J, Krčmová I. Interpretujeme správně počty eozinofilů v periferní krvi u pacientů s bronchiálním astmatem? Alergie. 2021;2:115-124.

5. Holguin F, Cardet JC, Chung KF et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi: 10.1183/13993003.00588-2019. PMID: 31558662.

6. Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140:1509-18. doi:10.1016/j.jaci.2017. 10. 005.

7. Lim HF, Nair P. Airway inflammation and inflammatory biomarkers. Semin Respir Crit Care Med. 2018; 9(1):56-63.

8. Krčmová I, Novosad J. Cílená biologická léčba bronchiálního astmatu. Farmakoterapie. 2018;14(1):94-103.

9. Busse WW, Holgate S, Kerwin E et al. Randomized, double‑blind, placebocontrolled study of brodalumab, a human anti‑IL- 17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294-1302.

10. Roberts G, Pfaar O, Akdis CA et al. EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73:765-798.

11. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2016. http://www.ginaasthma.org. Accessed 16 Aug 2016.

12. Agache I, Lau S, Akdis CA et al.EAACI Guidelines on Allergen Immunotherapy: House dustmite- driven allergic asthma.Allergy.2019;74:855-873.

13. Kristiansen M, Dhami S, Netuveli G et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta‑analysis. Pediatr Allergy Immunol. 2017;28:18-29.

14. Larenas‑Linnemann D, Luna‑Pech JA. What you should not miss from the systematic reviews and meta‑analyses on allergen- specific immunotherapy in 2017. Curr Opin Allergy Clin Immunol. 2018;18:168-176.

15. Rybniček O, Seberová E. Průvodce alergenovou imunoterapií. 3. přepracované vydání. Tigis 2021, 978-80-87323-18-2.

16. Niggemann B, L Jacobsen L, Dreborg S, Five‑year follow‑up on the PAT study: specific immunotherapy and long‑term prevention of asthma in children. Allergy 2006 Jul;61(7):855-9.

17. Durham SR, Emminger W, Kapp A et al. SQ‑standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-25. e5.

18. Dahl R, Roberts G, de Blic, J et al. SQ grass sublingual allergy immunotherapy tablet for disease‑modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy Asthma Proc. 2016;37:92-104.

19. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass SLIT‑tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy and Clinical Immunology. 10.1016/j.jaci.2017. 06. 014

20. Wahn U. Preventing new sensitization and asthma onset by allergen immunotherapy: The current evidence. Curr Opin Allergy Clin Immunol. 2017;17:443-446.

21. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double‑blind, placebo‑controlled trial. J Allergy Clin Immunol. 2014;134(3):568-75. e7.

22. De Blay F, Kuna P, Prieto L et al. SQ‑HDM SLIT‑tablet (ALK) in treatment of asthma - post hoc results from a randomised Respir Med. 2014;108:1430-1437.

23. Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: a Randomized Clinical Trial. JAMA. 2016;315(16):1715-25.

24. Demoly P, Emminger W, Rehm D et al. Effective treatment of house dust mite‑induced allergic rhinitis with 2 doses of the SQ HDM SLIT‑tablet: Results from a randomized, double‑blind, placebo‑controlled phase III trial. J Allergy Clin Immunol. 2016;137(2):444-451.

25. Virchow JC, Backer V, Kuna P et al. SQ‑HDM SLIT‑tablet is effective in the treatment of allergic asthma: results from a DBPC phase III tria((MITRA). JAMA. 2016;315:1715-1725.

26. Calderón MA, Linneberg A, Kleine‑Tebbe J et al. Respiratory allergy caused by house dust mites: What do we really know? Journal of Allergy and Clinical Immunology. 2015;136(1):38-48.

27. Hrubiško M., Krčmová I. Roztočová alergie – lze léčit lépe? Alergie. 2019;4:245-253.

28. Caimmi D, Demoly P. A review of allergen immunotherapy in asthma. Allergy Asthma Proc 43:310-313, 2022; doi: 10.2500/aap.2022. 43. 210113)

29. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long‑term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real‑world database analysis. Allergy. 2018;73(1):165-77.

30. Fritzsching B, Contoli M, Porsbjerg C et al. Long‑term real‑world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study. The Lancet Regional Health – Europe, February 2022; Volume 13:100275-100283, https://doi.org/10.1016/j.lanepe.2021.100275

31. Krčmová I, Čáp P, Kučera P et al. Stanovisko ČSAKI k sublinguální alergenové imunoterapii v léčbě inhalačních alergií. Alergie. 2022;2:138-142.